In both CRC and GC, patients with lower expression of FasL responded better to chemotherapy than patients with higher expression of FasL (Table 1, Figure 1G and 1H), indicating that Fas signaling may contribute to chemoresistance of GI cancer. This evidence concerns the gene FASLG and colorectal carcinoma.